港股異動︱醫療器械板塊繼續上漲 康德萊醫械(1501.HK)等三股再創上市新高
格隆匯1月16日丨醫療器械板塊繼續上漲,康德萊醫械(1501.HK)升5.56%領漲,愛康醫療、威高股份漲逾1%,康德萊醫械、愛康醫療、春立醫療三股再創上市新高,其中,愛康上市2年已累漲逾6倍,愛康、春立年初以來半個月已累漲逾40%。2019年7月4日,國家藥監局和國家衞生健康委員會聯合發佈了《關於發佈〈定製式醫療器械監督管理規定(試行)〉的公告》,該規定自2020年1月1日起生效。明確對定製式醫療器械實行備案管理,並對生產、使用定製式醫療器械的生產企業和醫療機構均提出了明確要求,明確定製式醫療器械不得委託生產。此外,本週二(14日),國家藥監局在京召開2019年第四季度醫療器械上市後監管風險會商會。會議要求進一步推行和完善風險會商機制,強化醫療器械風險防控,提升醫療器械質量安全保障水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.